A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa
The purpose of this study is to evaluate the efficacy and safety of Povorcitinib (INCB054707) in participants with moderate to severe Hidradenitis Suppurativa (HS) over a 12-week placebo controlled period, followed by a 42-week extension period.
Inclusion Criteria:
Exclusion Criteria:
Ostrava - Poruba, 708 52, Czechia
Itabashi-ku, 173-8610, Japan
Kurume-shi, 830-0011, Japan
Nakagami-gun, 903-0215, Japan
Nishinomiya-shi, 663-8186, Japan
Shinjuku-ku, 160-0023, Japan